


PF-3882845

Cat. No.:	HY-12738
CAS No.:	1023650-66-9
Molecular Formula:	C ₂₄ H ₂₂ ClN ₃ O ₂
Molecular Weight:	419.9
Target:	Mineralocorticoid Receptor; Progesterone Receptor
Pathway:	Metabolic Enzyme/Protease; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PF-3882845 is a remarkably high affinity selective and orally efficacious mineralocorticoid receptor (MR binding IC ₅₀ =2.7 nM) antagonist for hypertension and nephropathy. PF-3882845 also binds to progesterone receptor (PR) with the binding IC ₅₀ of 310 nM ^[1] .								
IC₅₀ & Target	IC ₅₀ : 2.7 nM (mineralocorticoid receptor), 310 nM (progesterone receptor) ^[1]								
In Vivo	<p>PF-3882845 reduces blood pressure, decreases urinary albumin, and protects kidney in Dahl SS rat^[1].</p> <p>PF-3882845 exhibits moderate oral bioavailability (F 86%) following oral administration (2 mg/kg) in male Sprague-Dawley rats^[1].</p> <p>PF-3882845 exhibits terminal elimination half-lives (T_{1/2} 1.7 h) due to high plasma clearance (CL 9.8 mL/min/kg) combined with large volumes of distribution (V_{dss} 1.4 mL/kg respectively) following intravenous administration (2 mg/kg) in male Sprague-Dawley rats^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Dahl salt sensitive (SS) rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10, 40, and 100 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Orally via gavage; twice a day; for 21 days</td> </tr> <tr> <td>Result:</td> <td>Significant blood pressure reduction was observed with 10 mg/kg. Most noticeably, rats dosed at 40 and 100 mg/kg had negligible increase in blood pressure over 21 days in the presence of high salt.</td> </tr> </table>	Animal Model:	Male Dahl salt sensitive (SS) rats ^[1]	Dosage:	10, 40, and 100 mg/kg	Administration:	Orally via gavage; twice a day; for 21 days	Result:	Significant blood pressure reduction was observed with 10 mg/kg. Most noticeably, rats dosed at 40 and 100 mg/kg had negligible increase in blood pressure over 21 days in the presence of high salt.
Animal Model:	Male Dahl salt sensitive (SS) rats ^[1]								
Dosage:	10, 40, and 100 mg/kg								
Administration:	Orally via gavage; twice a day; for 21 days								
Result:	Significant blood pressure reduction was observed with 10 mg/kg. Most noticeably, rats dosed at 40 and 100 mg/kg had negligible increase in blood pressure over 21 days in the presence of high salt.								

REFERENCES

[1]. Meyers MJ, et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem. 2010 Aug 26;53(16):5979-6002.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA